Home > For Consumers > Aldosterone antagonists for preventing...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet].

Aldosterone antagonists for preventing the progression of chronic kidney disease

This version published: 2014; Review content assessed as up-to-date: January 30, 2013.

Link to full article: [Cochrane Library]

Plain language summary

People who have chronic kidney disease (CKD) are at increased risk of heart disease and worsening kidney disease needing treatment with dialysis or a kidney transplant. Increased amounts of protein in the urine are a sign of kidney stress and are linked to a greater chance of worsening kidney function. Treatments that lower urine protein levels and protect kidney function are available and include angiotensin converting enzyme inhibitors and angiotensin receptor blockers. However, protection of kidney function with these two drugs may be incomplete and adding aldosterone blockers (for example, spironolactone or eplerenone) may better protect kidney function. The use of numerous drugs may also increase side‐effects. This review of available trials showed that adding aldosterone antagonist treatment to standard therapy reduced protein release into the urine and lowered blood pressure but had uncertain effects on kidney function and survival. Treatment also increases the amount of potassium in the blood which may require treatment changes, extra blood tests and is potentially harmful. Whether aldosterone blockers protect kidney function to lower the chances needing dialysis or kidney transplantation or prevent heart disease in people who have CKD is unclear and not answered by existing research.

Abstract

Background: Treatment with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is increasingly used to reduce proteinuria and retard the progression of chronic kidney disease (CKD). However, resolution of proteinuria may be incomplete with these therapies and the addition of an aldosterone antagonist may be added to further prevent progression of CKD. This is an update of a review first published in 2009.

Objectives: To evaluate the effect of aldosterone antagonists (both selective (eplerenone) and non‐selective (spironolactone)) alone or in combination with ACEi or ARB in adults who have CKD with proteinuria (nephrotic and non‐nephrotic range) on: patient‐centred endpoints including major cardiovascular events, hospitalisation and all‐cause mortality; kidney function (proteinuria, glomerular filtration rate (GFR), serum creatinine, and need for renal replacement therapy; and adverse events (including gynaecomastia and hyperkalaemia).

Search methods: For this update, we searched the Cochrane Renal Group's Specialised Register to 30 January 2013 using search terms relevant to this review.

Selection criteria: We included randomised controlled trials (RCTs) and quasi‐RCTs that compared aldosterone antagonists alone or in combination with ACEi or ARB (or both) with other anti‐hypertensive strategies or placebo.

Data collection and analysis: Two authors independently assessed study quality and extracted data. Data were summarised using random effects meta‐analysis. We tested for heterogeneity in estimated treatment effects using the Cochran Q test and I² statistic. We expressed summary treatment estimates as a risk ratio (RR) for dichotomous outcomes together with their 95% confidence intervals (CI) and mean difference (MD) for continuous outcomes, or standardised mean difference (SMD) when different scales were used.

Main results: We identified 27 studies (1549 participants) that were eligible for inclusion. These studies provided no data relating to aldosterone antagonists in addition to ACEi or ARB (or both) on patient‐level outcomes including major cardiovascular events and mortality and progression to end‐stage kidney disease (ESKD) requiring dialysis or transplantation.

Compared with ACEi or ARB (or both), non‐selective aldosterone antagonists (spironolactone) combined with ACEi or ARB (or both) significantly reduced 24‐hour protein excretion (11 studies, 596 participants): SMD ‐0.61, 95% CI ‐1.08 to ‐0.13). There was a significant reduction in both systolic and diastolic blood pressure (BP) at the end of treatment with additional non‐selective aldosterone antagonist therapy (systolic BP (10 studies, 556 participants): MD ‐3.44 mm Hg, 95% CI ‐5.05 to ‐1.83) (diastolic BP (9 studies, 520 participants): MD ‐1.73 mm Hg, 95% CI ‐2.83 to ‐0.62).

However, we found that aldosterone antagonist treatment had imprecise effects at the end of treatment on GFR (9 studies, 528 participants; MD ‐2.55 mL/min/1.73 m², 95% CI ‐5.67 to 0.51), doubled the risk of hyperkalaemia (11 studies, 632 patients): RR 2.00, 95% CI 1.25 to 3.20; number needed to treat for an additional harmful outcome (NNTH): 7.2, 95% CI 3.4 to ∞) and increased the risk of gynaecomastia compared to ACEi or ARB (or both) (4 studies, 281 patients): RR 5.14, 95% CI 1.14 to 23.23; NNTH: 14.1, 95% CI 8.7 to 37.3).

Most studies enrolled few patients (range 12 to 268) and were powered to observe differences in surrogate end points rather than patient‐focused outcomes. Nine studies had a cross‐over design and the majority of studies did not adequately report study methods to assess methods and study quality.

Authors' conclusions: Aldosterone antagonists reduced proteinuria and blood pressure in adults who had mild to moderate CKD and were treated with ACEi or ARB (or both), but increase hyperkalaemia and gynaecomastia. Whether adding aldosterone antagonists to ACEi or ARB (or both) reduced the risk of major cardiovascular events or ESKD in this population is unknown.

Editorial Group: Cochrane Kidney and Transplant Group.

Publication status: New search for studies and content updated (conclusions changed).

Citation: Bolignano D, Palmer SC, Navaneethan SD, Strippoli GFM. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD007004. DOI: 10.1002/14651858.CD007004.pub3. Link to Cochrane Library. [PubMed: 24782282]

Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PMID: 24782282

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...